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VASCULAR BIOLOGY
A revised model for the secretion of tPA and cytokines from cultured
endothelial cells
Laura Knipe,1 Athinoula Meli,1 Lindsay Hewlett,1 Ruben Bierings,1 John Dempster,2 Paul Skehel,3 Matthew J. Hannah,1 and
Tom Carter1
1Medical Research Council, National Institute for Medical Research, London; 2Department of Physiology and Pharmacology, University of Strathclyde, Glasgow;
and 3Centre for Integrative Physiology, University of Edinburgh, Edinburgh, United Kingdom
Endothelial cells are reported to con-
tain several distinct populations of regu-
lated secretory organelles, including
Weibel-Palade bodies (WPBs), the tissue
plasminogen activator (tPA) organelle,
and the type-2 chemokine-containing or-
ganelle. We show that the tPA and type-2
organelles in human endothelial cells rep-
resent a single compartment primarily
responsible for unstimulated secretion of
tPA or, in cells exposed to interleukin-1
(IL-1), the cytokines IL-8, IL-6, monocyte
chemoattractant protein-1 (MCP-1), and
growth-regulated oncogene- (GRO-).
This compartment was distinct from
WPBs in that it lacked detectable von
Willebrand factor, P-selectin, Rab27a, or
CD63 immunoreactivity, displayed no
time-dependent decrease in intragranule
pH, underwent detectable unstimulated
exocytosis, and was very poorly respon-
sive to Ca2-elevating secretagogues.
WPBs could also contain tPA, and in
IL-1–treated cells, IL-8, IL-6, MCP-1, and
GRO-, and were the primary source for
histamine or ionomycin-stimulated secre-
tion of these molecules. However, analy-
sis of the storage efficiency of cytokines
and tPA revealed that all were very poorly
stored compared with von Willebrand fac-
tor. The nonmammalian, nonsecretory
protein EGFP, when expressed in the se-
cretory pathway, also entered WPBs and
had a storage efficiency similar to tPA
and the cytokines tested. Based on these
data, we proposed a revised model for
storage and secretion of cytokines and
tPA. (Blood. 2010;116(12):2183-2191)
Introduction
Several studies suggest that endothelial cells (ECs) possess several
distinct populations of regulated secretory organelles (RSOs) in
which different subsets of bioactive peptides and proteins are
stored, trafficked, and rapidly secreted in response to physiologic
stimuli. These include (1) Weibel-Palade bodies (WPBs) whose
major cargo protein is von Willebrand factor (VWF)1; (2) a small
punctate organelle, morphologically distinct from WPBs, lacking
endogenous VWF immunoreactivity but containing the anti-
coagulant protein tissue plasminogen activator (tPA; the tPA
organelle)2-4; and (3) a small punctate organelle, reported to
specifically contain the small chemotactic cytokines growth-
regulated oncogene- (GRO-) and monocyte chemoattractant
protein 1 (MCP-1) and termed the type-2 granule.5 The presence of
distinct populations of RSOs within the same cell is not uncom-
mon6-8 and may allow the stimulated release of diverse bioactive
molecules to be differentially controlled. If distinct populations of
RSOs do exist in ECs, then a careful examination of their properties
would provide insights into how trafficking and secretion of
specific groups of bioactive molecules are regulated.
WPBs are the best characterized RSO of ECs. After their
formation at the trans-Golgi network (TGN), WPBs accumulate in
the cytoplasm and can remain within the cell for long periods of
time (1-2 days).9,10 By these criteria, we define WPBs as true
storage organelles. Under resting conditions, WPBs undergo a very
slow process of basal exocytosis,10 undetectable in optical record-
ings from individual live cells.11 However, their rate of exocytosis
is rapidly increased in response to external stimuli that elevate
intracellular free calcium ion concentrations ([Ca2]i).11 A punctate
tPA-containing organelle has been described as the tPA-storage
organelle in endothelium,2 from which stimulated tPA secretion is
proposed to arise.2,3,12 However, tPA may also reside within
WPBs,3,12,13 and uncertainty still remains as to which of these
2 compartments is primarily responsible for stimulated tPA secre-
tion. The properties of the tPA-strorage organelle remain poorly
defined. Is it, like the WPB, a true long-term storage organelle, and
can it undergo robust stimulated exocytosis? Optical studies show
that the tPA organelle undergoes significant unstimulated exocyto-
sis,14 suggesting that they are not retained within the cell as efficiently as
WPBs under resting conditions.11 Direct optical analysis of the kinetics
and extent of stimulated exocytosis of the tPA organelle are still lacking.
The type-2 chemokine-containing organelle is morphologically similar
to the tPA organelle, but the lack of colocalization of overexpressed tPA
with punctate GRO-–containing organelles led to the conclusion that
they comprised a distinct population of RSOs.5
We have reexamined the composition and properties of the tPA
organelle, the type-2 chemokine-containing organelle, and WPBs
in human umbilical vein endothelial cells (HUVECs). From these
data, we propose a revised model for secretion of tPA and cytokines
from ECs. We question whether cytokines, detectable in WPBs
under conditions where their expression levels are up-regulated, are
sorted to this cellular compartment. Instead, we suggest that such
molecules are efficiently excluded from WPBs and that their
presence in WPBs arises from an exclusion mechanism that is
almost, but not quite, 100% efficient.
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Methods
Tissue culture and transfection
Primary HUVECs were purchased, grown, Nucleofected (Lonza Cologne
AG), plated, and maintained for live-cell imaging or immunofluorescence
as previously described.15,16 Cells were used between 6 and 48 hours after
Nucleofection depending on the experiment.
Antibodies, reagents, immunocytochemistry, and confocal
microscopy
Reagents were purchased from Sigma-Aldrich unless stated otherwise.
tPA-EGFP, proregion-EGFP, and proregion-mRFP were made as previously
described.15-17 Human Rab6, Rab8, Rab10, Rab11, and Rab27a cDNAs
(cDNA Resource Center; www.cdna.org) were ligated as HindIII/ApaI
fragments into Myc-C3 to generate N-terminally Myc-tagged versions.
Myc-C3 was derived from EGFP-C3 (Clontech) by removing the EGFP
cDNA using AgeI/BsrGI and inserting the MYC epitope coding sequence
using a double-stranded linker made by annealing the oligos 5-
ccggtatggcatcaatgcagaagctgatctcagaggaggacct-3 (forward) and 5-gtacag-
gtcctcctctgagatcagcttctgcattgatgccata-3 (reverse). Human Rab27a cDNA
was cloned into mRFP-C3 as a HindIII/ApaI fragment to make mRFP-
hRab27a. mRFP-C3 was constructed from EGFP-C3 by exchanging the
fluorophore encoding region with a AgeI/BsrGI fragment of PCR amplified
mRFP1 described previously.18 LumEGFP was cut from a vector provided
by Dr David Stevens (University of Bristol, Bristol, United Kingdom19) and
recloned into NheI/BsRGI digested pEGFP-N1 (Clontech). Human interleu-
kin-8 (IL-8; image ID 3882471) and GRO- (image ID 3856841) image
clones were from Geneservice. Rabbit anti–human VWF was from Dako. A
sheep antihuman VWF antibody, a mouse antihuman VWF antibody
(MCA127), a sheep anti-tPA antibody, a sheep anti-GFP antibody, and a
mouse anti–P-selectin antibody (AK6) were from AbD Serotec. The
antibodies H4A3 (to LAMP-1) and H5C6 (to CD63), developed by J.T
August and J.E.K. Hildreth, were from the Developmental Studies Hybrid-
oma Bank, developed under National Institute of Child Health and Human
Development and maintained by the University of Iowa (Iowa City, IA). An
antibody to the transferrin receptor (H64.8) was from Zymed Laboratories.
A rabbit anti-GFP antibody was from Invitrogen. Recombinant human
IL-1 (rhIL-1), rhIL-4, goat antibodies to human IL-6, IL-8, MCP-1, and
eotaxin-3, and a mouse antibody to human GRO- (clone 20326) were from
R&D Systems. rhIL-6, rhIL-8, and a rabbit antibody to human GRO-were
from PeproTech. Rab27a antibody was from BD Transduction Laboratories
(catalog no. 610595/6). Fluorophores or horseradish peroxidase (HRP)–
coupled secondary antibodies were from Jackson ImmunoResearch Labora-
tories. Donkey anti–goat IgG coupled to IR800 was from LI-COR. Single
optical section confocal images of fixed cells mounted in mowiol (Harlow
Chemical Company Ltd) were acquired using a Leica TCS-SP2 confocal
microscope equipped with a PLAPO 100/1.4 numeric aperture oil
objective and Leica Version 2.61 software as previously described.18 Images at
different excitation wavelengths were acquired sequentially with 14 to 25 frame
averaging using nonsaturating excitation and electronic zoom 1-25. Images
were exported to and processed in Adobe Photoshop CS4 Version 11.0.
Stimulation protocols and ELISAs
Endogenous cytokines were up-regulated by incubating with rhIL-1
(24 hours or 48 hours, 1 ng/mL) or rhIL-4 (24 hours, 20 ng/mL) in full
growth medium (HGM). For experiments with brefeldin-A (BFA), cells
were transferred into serum and bicarbonate-free M199 (Invitrogen),
containing 20mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
(pH 7.4) and 5M BFA or vehicle (0.05% EtOH) and incubated for
60 minutes before fresh media (with BFA or vehicle) was exchanged. Ten
minutes later, fresh media containing 100M histamine or vehicle was
added, and this was collected 10 minutes later for assay. For cycloheximide
(CHX) experiments, cells were transferred into fresh HGM containing
rhIL-1 and 5M CHX or vehicle control and cultured for a further
24 hours. Cells were then transferred into serum and bicarbonate-free M199
and treated as described for BFA-treated cells (see earlier in this paragraph),
except 5M CHX replaced BFA, and cells were stimulated with 100M
histamine, 2M ionomycin, or vehicle. All medium and lysate samples
were prepared and stored as previously described.18
IL-8, IL-6, MCP-1, or GRO- from media or lysate samples was
assayed in triplicate using commercial enzyme-linked immunosorbent
assay (ELISA) kits (human IL-8 and GRO- kits from Antigenix America,
PeliKine compact human IL-6 kit from Sanquin, and human MCP-1 and
GRO- kits from PeproTech). ELISAs were performed according to the
manufacturer’s instructions, with the exception that washes and blocking
were carried out using a Tween-ELISA buffer (phosphate-buffered saline
containing 0.1% Tween-20, 0.2% gelatin, and 1mM ethylenediaminetetraace-
tic acid). Streptavidin-HRP was either included in the ELISA kits or was
from Jackson ImmunoResearch. HRP activity was detected colorimetrically
using a 0.15% (wt/vol) solution of o-phenylediamine dihydrochloride in a
citrate/phosphate buffer containing 1% Triton X-100 and 0.012% (weight/
volume) H2O2 added just before use. Absorbance was recorded using a
VERSAmax microplate reader (MDS Analytical Technologies). Standard
curves were made in serum-free N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid–buffered M199 or in lysis buffer. EGFP was assayed
using a sandwich ELISA. Plates were coated with a sheep anti-GFP
antibody. Bound GFP was detected with a rabbit anti-GFP followed by a
donkey anti–rabbit HRP-conjugated secondary. Standard curves were made
from dilutions of recombinant bacterially produced GFP. tPA from media
samples were assayed by sandwich ELISA. Plates were coated with a sheep
anti-tPA coating antibody (Serotec). Bound tPA was detected with a sheep
anti–tPA-HRP conjugate (Quadratech). Standard curves were constructed
in serum and bicarbonate-free M199 from a 1:10 dilution of HGM taken
from HUVECs incubated for 24 hours with 3mM Na-butyrate.
Storage efficiency for IL-8, IL-6, MCP-1, GRO-, VWF, tPA,
and lumEGFP
A storage efficiency for IL-8, IL-6, MCP-1, GRO-, and lumEGFP was
estimated as follows. Cells were used after 24 hours of treatment with IL-1
(1 ng/mL), at which time up-regulation of cytokine expression had reached
a steady state. Under these conditions, cells were synthesizing cytokines at
the same rate at which they are secreted (ie, there was a constant flux of
material through all compartments),20 with no additional accumulation of
material in cell lysates or differences in secretion between 24 and 48 hours
(supplemental Figure 1A, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). At this point,
cells were either placed in fresh media containing 5M CHX (and IL-1)
and cultured for a further 24 hours or treated for 1 hour with BFA (5M), at
which time cell lysates were harvested. BFA rapidly (within 5 minutes)
disrupts endoplasmic reticulum (ER) to Golgi transport, preventing exit of
newly synthesized material from the ER without affecting post-Golgi
vesicle secretion (see Figure 5) and protein biosynthesis. Therefore, the
amount of material accumulated in lysates during 1 hour of BFA treatment
reflects the amount of material synthesized during that time period (“a” in
supplemental Figure 1B; assuming no degradation), and the amount of
material potentially synthesized in 24 hours can be estimated by multiply-
ing this value (“a”) by 24. Meanwhile, the amount of that material
remaining within cells after 24 hours of exposure to CHX was defined as the
stored material (“b” in supplemental Figure 1B). This use of BFA to
estimate total synthetic capacity was used in preference to measuring
accumulated material in cell lysates and media over a 24-hour period
because of uncertainties over stability of secreted proteins in the media over
such long time periods.10 Storage efficiency was estimated by taking the
ratio of the stored material (“b”) and the amount of material potentially
synthesized in 24 hours (“a”). A storage efficiency for VWF, tPA, and
lumEGFP was determined by pulse-chase and immunoprecipitation meth-
ods. For VWF and tPA, cells were metabolically labeled for 30 minutes
(50 Ci/mL Expre35S35S protein labeling mix, PerkinElmer Life and
Analytical Sciences), followed by incubation for 24 hours before harvesting
media and lysates for immunoprecipitation of tPA and VWF. Immunopre-
cipitations on media and lysates were performed sequentially using a sheep
anti-tPA antibody bound to protein G-Sepharose (Generon) followed by a
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rabbit anti-VWF antibody (Dako) bound to protein A-Sepharose. Immuno-
precipitates were eluted and run on a 10% gel (for tPA) or 6% gel (for
VWF). Gels were stained, dried, and exposed to storage phosphor plates as
described previously.10 For LumEGFP, cells were Nucleofected with
LumEGFP 24 hours before 35S labeling, followed by a further incubation of
24 hours before harvesting. EGFP immunoprecipitations used a rabbit
anti-GFP antibody coupled to protein A-Sepharose, and the eluted immuno-
precipitates were run on a 12% gel. Bands corresponding to VWF, tPA, or
EGFP were quantified using ImageJ Version 1.41o software (http://rsb.
info.nih.gov/ij/), and storage efficiency was calculated from material in cell
lysates (after 24 hours) as a proportion of total material (lysate plus media).
Fluorescence imaging of tPA-granules in living HUVECs
Experiments to quantify the effect of BFA treatment on numbers of
tPA-EGFP puncta or WPBs (labeled with proregion-EGFP) were carried
out at 37°C using a Deltavision Imaging system (Applied Precision) as
previously described.15,16 Z-series image stacks composing 7 or 8 optical
sections at 0.3-m intervals were obtained approximately 3 minutes after
addition of BFA or vehicle and subsequently every 3 to 5 minutes over the
following approximately 60 to 90 minutes. The numbers of fluorescent tPA
organelles or WPBs in the cell were determined as described in “Data
analysis and measurements.” Epifluorescence or total internal reflection
fluorescence imaging of [Ca2]i and tPA organelle (tPA-EGFP) or WPB
(proregion-EGFP) exocytosis was carried out in Fura-2-loaded cells as
previously described11 but using an Olympus UPLSAPO  100 1.40NA
objective. Cells coexpressing tPA-EGFP and either mRFP-hRab27a or
proregion-mRFP (24 hours after Nucleofection) were sequentially illumi-
nated at 355 plus or minus 7 nm, 380 plus or minus 7 nm (Fura-2), 470 plus
or minus 20 nm (EGFP), and 555 plus or minus 20 nm (mRFP) using a
monochromator (Cairn Research). A custom dichroic mirror (Chroma,
51019  400DCLP) and EGFP/DsRed dual-band emission filter were used.
The custom-built objective-based total internal reflection fluorescence
system21,22 was incorporated into the epifluorescence microscope with
488 nm (Point Source) and 561 nm laser light sources (GLC-050-561).
Illumination was synchronized with image capture using Winfluor soft-
ware (http://spider.science.strath.ac.uk). Images were acquired at 30 or
40 (reduced pixel area) frames/sec.
pH in the tPA organelle
The resting pH in tPA-EGFP-containing punctate organelles was deter-
mined from epifluorescence measurements of the steady-state fluorescence
of EGFP and the maximum fluorescence of the organelle EGFP, obtained
after acute application of the weak base ammonium chloride (NH4Cl;
5-10mM), using parameters describing the relationship between EGFP
fluorescence and pH determined previously (pKa of 5.84 and nH of 0.7411).
Resting pH within tPA-EGFP punctate granules was also determined from
organelles undergoing exocytosis into extracellular media at pH 7.4 as
previously described.11
Data analysis and measurements
Image analysis was carried out in Winfluor (http://spider.science.strath.
ac.uk) or ImageJ. The number of tPA-EGFP puncta or WPBs in cells during
BFA treatment were counted manually using the ImageJ pointpicker
pluggin (http://rsb.info.nih.gov/ij/plugins/index.html). Optical sections at
each point in time-lapse sequences were projected within pointpicker,
allowing granules in different optical planes to be identified and marked.
Numbers of granules at each time point were counted twice and the average
taken. Extent of histamine or ionomycin-evoked degranulation was esti-
mated as previously described.11 Dataset plotting, fitting, and analysis were
performed in Microcal Origin 7.5 (OriginLab Corporation). Results are
expressed as mean plus or minus SD unless indicated otherwise. Statistical
differences (at 95% confidence limit) between population means were
determined using a nonpaired 2-way t test.
Results
Expression of tPA-EGFP labels the endogenous tPA organelle
and WPBs in HUVECs
We first compared the subcellular localization of endogenous tPA
immunoreactivity or expressed tPA-EGFP fluorescence with WPB
marker proteins (VWF, P-selectin, CD63, and Rab27a). Figure
1A-C shows tPA immunoreactivity in HUVECs counterstained for
VWF (Figure 1A), P-selectin (Figure 1B), or CD63 (Figure 1C).
Figure 1D-F shows tPA-EGFP fluorescence counterstained as in
Figure 1A-C. In both cases, numerous small punctuate organelles
lacking the WPB marker proteins were seen. Endogenous Rab27a
was present on WPBs but not punctate tPA-containing organelles
(Figure 2A). Coexpression of tPA-EGFP and myc-hRab27a con-
firmed that punctate tPA-EGFP containing organelles do not recruit
Rab27a (Figure 2B). Punctate tPA-EGFP organelles did not
colocalize with markers for ER exit sites (myc-sec23), ER to Golgi
transport vesicles (Rab1), early and recycling endosomes (trans-
ferrin receptor), and lysosomes (Lamp1; data not shown). tPA-
EGFP puncta also failed to colocalize with expressed Myc-tagged
Rab proteins associated with the Golgi apparatus or constitutive
secretory pathway (Rab 6, 8, 10, 11, and 17; data not shown).
Figure 1. The tPA organelle lacks endogenous VWF, P-selectin, and CD63.
(A-C) Representative examples of individual HUVECs labeled with a specific
antibody to tPA (green and top panels of grayscale inserts) and VWF (A), P-selectin
(B), or CD63 (C) (red and bottom panel of grayscale inserts). (D-F) EGFP
fluorescence (green and top panels of grayscale inserts) in cells expressing
tPA-EGFP (24 hours after Nucleofection) and counter-labeled with specific antibodies
to VWF (D), P-selectin (E), or CD63 (F) (red and bottom panel of grayscale inserts).
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In addition to the small punctate organelles, tPA immunoreactiv-
ity (Figure 1A) or expressed tPA-EGFP (Figures 1, 2; supplemental
Figure 2) could be observed in some WPBs. The presence of
tPA-EGFP in WPBs was dependent on time after Nucleofection;
tPA-EGFP was absent from WPBs at early times (4-6 hours;
supplemental Figure 2), seen in a variable but small number of
WPBs at 24 hours (eg, Figure 1; supplemental Figure 2) and more
prominently present in WPBs at 48 hours after Nucleofection
(supplemental Figure 2).
The tPA organelle and the type-2 chemokine-containing
organelle are the same and can also contain IL-8 or eotaxin-3
A striking and consistent feature in cells expressing tPA-EGFP was
the accumulation of fluorescent puncta and material at the Golgi
region,12,14 illustrated by a close association with the TGN marker
protein TGN46 (Figure 3Ai). The same pattern was seen for
endogenous tPA immunoreactivity in cells expressing detectable
amounts (Figure 3Aii).2,3,14 The accumulation of material in or
around the Golgi apparatus is also a feature of cytokine up-
regulation in ECs5,23-25 and was very apparent for GRO- and
MCP-1 in the recent study describing the novel type-2 organelle of
ECs.5 In that study, transfection with a tPA expression vector failed
to produce any visible Golgi accumulation of tPA in the images
shown, suggesting that exogenous tPA may not have been ex-
pressed correctly in those cells. Down-regulation of endogenous
tPA expression in HUVECs by IL-126 prevented us from directly
colocalizing endogenous tPA immunoreactivity within cytokine-
containing puncta. Instead, we used exogenous expression of tPA,
tagged with EGFP, allowing independent assessment of expression
and localization. tPA-EGFP fluorescence colocalized with punctate
GRO- or MCP-1 immunoreactivity (Figure 2Bi-ii). tPA-EGFP
fluorescence also colocalized with punctate endogenous IL-8 or
eotaxin-3 immunoreactivity (Figure 2Biii-iv). In IL-4–treated cells,
endogenous tPA immunoreactivity colocalized with punctate
eotaxin-3 immunoreactivity (supplemental Figure 3A). Exog-
enously expressed hIL-8 also colocalized with endogenous tPA-
containing puncta (supplemental Figure 3B). Triple staining for
Figure 2. The tPA-EGFP-containing organelle does not recruit endogenous or
expressed Rab27a. (A) An individual HUVEC triple labeled with specific antibodies
to tPA (green), Rab27a (red), and VWF (blue). Grayscale images of the regions i and
ii are shown on the right. (B) Twenty-four hours after Nucleofection with tPA-EGFP
(green; EGFP fluorescence) and myc-Rab27a (red). tPA-EGFP is seen in Rab27a-
negative puncta and also occasionally in some WPBs, identified by their distinctive
rod-shape (large arrowheads). (A-B) Grayscale inserts: regions indicated by white
boxes on the color images.
Figure 3. The tPA-EGFP organelle and type-2 organelle are the same. (A) Repre-
sentative confocal images of the Golgi region of transfected cells expressing
tPA-EGFP (Ai; EGFP fluorescence green in color-merged panel) or nontransfected
cells labeled for endogenous tPA immunoreactivity (Aii; green in color-merged panel,
cells were exposed to 3mM Na butyrate, 24 hours to up-regulate endogenous tPA
expression levels13) and counterstained with a specific antibody to TGN46 (red in
color-merged panels). (B) Cells stained for endogenous GRO- (i), MCP-1 (ii), IL-8
(iii), or eotaxin-3 (iv) immunoreactivity (red in color-merged images) in cells express-
ing tPA-EGFP (EGFP fluorescence green in color-merged images). Regions indi-
cated by the white boxes are shown in grayscale to the right of each image. Cells
were pretreated with IL-1 (GRO-, MCP-1, and IL-8) or IL-4 (eotaxin-3) as
described in “Stimulation protocols and ELISAs.” (C) IL-8 (red and top panels in
grayscale images), GRO- (green and middle panels in grayscale images), and VWF
(blue and bottom panels in grayscale images) immunoreactivity in an IL-1-
pretreated cell. The white boxes indicate regions shown in grayscale to the right of the
color image.
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endogenous GRO-, IL-8, and VWF confirmed that GRO- and
IL-8 are contained within the same small VWF-negative punctate
structure (Figure 3Ci-ii small arrows on grayscale insets), although
it should be noted that IL-8 was also present in WPBs, consistent
with previous reports (Figure 2Ci-ii). We routinely found MCP-1
immunoreactivity in WPBs of IL-1–treated cells and low levels of
GRO- in some WPBs (supplemental Figure 3C-D).
IL-6 is present in both the tPA organelle and WPBs in
IL-1–treated HUVECs
To address whether the tPA organelle might represent a common
compartment for inflammatory molecules in ECs exposed to proinflam-
matory cytokines, we determined the subcellular localization of IL-6,
whose endogenous levels are also up-regulated by IL-127-29 (and
supplemental Figure 1Aii). After IL-1 treatment, a large increase in
IL-6-specific immunoreactivity was seen in the Golgi region, small
puncta, and numerous WPBs (supplemental Figure 4B-C). Figure 4A-B
shows in detail the subcellular localization of IL-6 immunoreactiv-
ity in individual HUVECs. Expressed tPA-EGFP colocalized with
punctate IL-6 immunoreactivity (Figure 4C), and triple staining for
GRO-, IL-6, and VWF confirmed that endogenous GRO- and
IL-6 are contained within the same punctate structures.
The tPA organelle is not a long-term storage organelle
Disruption of ER to Golgi transport by BFA30,31 rapidly prevents
formation of new secretory granules and was used to probe the
longevity of post-Golgi tPA organelles. Live HUVECs expressing
tPA-EGFP 6 hours after Nucleofection were used because at this
time point tPA-EGFP was seen only in punctate tPA organelles and
not WPBs (supplemental Figure 2). WPBs were studied in separate
cells expressing proregion-EGFP. Exposure of HUVECs to 5M
BFA led to complete disruption and dispersal of the Golgi
apparatus within 5 to 6 minutes (not shown). After 1 hour of BFA
treatment, there was no significant effect on numbers of fluorescent
WPBs or on basal or histamine-evoked secretion of proregion-
EGFP (Figure 5Ai-iv). In contrast, BFA (1 hour) led to a 95% reduc-
tion of tPA-EGFP puncta in live cells, with the decrease in puncta
after an approximately exponential time course (  15.8 minutes;
Figure 5Bi-iii). This was mirrored by a reduction in unstimulated
secretion of soluble tPA-EGFP (red symbols in Figure 5Biii-iv) or
of soluble GRO-, MCP-1, and IL-6 determined in separate
experiments (Figure 5Biv).
Figure 5. The tPA-EGFP organelle is a short-lived compartment from which
unstimulated secretion of tPA-EGFP and cytokines arises. (A-B) Representative
examples of fixed cells expressing proregion-EGFP (Ai-ii; 24 hours after Nucleofec-
tion) or tPA-EGFP (Bi-ii; 6-7 hours after Nucleofection) and stained with a specific
antibody to TGN46 (red in color images) in the absence of BFA (vehicle control; Ai
and Bi) or after 1-hour treatment with 5M BFA. Solid squares and line in panel Aiii
represent the mean numbers of WPBs, expressed as a percentage of the total
number at t  3 minutes after addition of BFA, present in cells at the times indicated
(n  6 cells; BFA added at t  0 minutes). Numbers of WPBs in vehicle-treated
control cells at 3, 15, and 60 minute time points, expressed in the same way, are
shown in open squares with dashed line (n  4 cells). (Biii) Similar data for
tPA-EGFP-containing puncta. In this case, the numbers of tPA-EGFP-containing
granules in BFA-treated cells are plotted individually because of differences in the
precise timing of measurements between experiments (n  9 cells). The solid black
line indicates a single exponential decline fitted to the pooled data for all cells.
Superimposed on the plot (red circles and red broken line) is the mean decrease in
unstimulated secretion of tPA-EGFP in cells treated with BFA. These data are
expressed as a percentage of control cells (vehicle-treated) at the times indicated
(n  4 independent experiments each carried out in duplicate; BFA added at t  0
minutes). Panels Aiv represent ELISA data for secreted EGFP from cells expressing
proregion-EGFP. Cells exposed to BFA or vehicle control (1 hour) were stimulated
with histamine or vehicle control (10 minutes) as indicated. Data shown are an
individual experiment carried out in triplicate and are representative of 3 separate
experiments. Panel Biv represents the mean decrease in unstimulated secretion
of IL-6 (), GRO- (f), and MCP-1 (F) from IL-1–treated cells exposed to BFA at
t  0. Data are normalized to that of vehicle control-treated cells at the times
indicated and represent data pooled from 3 or 4 independent experiments each
carried out in duplicate. For comparison, the data for unstimulated secretion of
tPA-EGFP in BFA treated-cells plotted in panel Biii are included in red.
Figure 4. IL-6 is present in the tPA-EGFP organelle and WPBs in IL-1–treated
cells. (A-B) Examples of single cells labeled for endogenous IL-6 (green in
color-merged panels) and endogenous VWF immunoreactivity (red in color-merged
panels). (C) Endogenous IL-6 immunoreactivity (red in color-merged image) in a
cell expressing tPA-EGFP (EGFP fluorescence green in color-merged image).
Regions indicated by the white boxes are shown in grayscale to the right of each
image. (D) Endogenous IL-6 (red and top panel in grayscale images), GRO- (green
and middle panel in grayscale images), and VWF (blue and bottom panel in grayscale
images) immunoreactivity in an IL-1-pretreated cell.
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The pH within the tPA organelle shows no time-dependent
acidification
WPBs are long-lived organelles and undergo substantial intragran-
ule acidification during maturation.11 The short-lived nature of
tPA-EGFP puncta led us to suppose that the intragranule pH in
these organelles might not be as acidic as that reached by mature
WPBs. The intragranule pH for tPA-EGFP-containing organelles
was determined using the NH4Cl pulse technique11 at 6 hours and
24 hours after Nucleofection, and compared with similar values
reported for WPBs at these times.11 At 6 hours, tPA-EGFP was
exclusively in non-WPB organelles; however, at 24 hours, some
WPBs also contained tPA-EGFP (supplemental Figure 2). To
distinguish tPA-EGFP-containing WPBs from punctate tPA or-
ganelles, cells were cotransfected with proregion-mRFP (that is
incorporated into newly formed WPBs) or mRFP-hRab27a (Rab27a
is recruited to all mature WPBs32; and Figure 2). Figure 6
summarizes the distribution of pH in tPA-EGFP puncta at 6 hours
and 24 hours, respectively. At both times, the mean pH for
individual tPA-EGFP puncta was similar. The mean intra-WPB
pH determined using tPA-EGFP 24 hours after Nucleofection
(Figure 6 open dashed bars) was similar to that obtained using
proregion-EGFP.11
Stimulated secretion and the storage efficiency of tPA
and cytokines
Although present in the short-lived punctate organelles, tPA and all
cytokines studied here could also be detected within WPBs. We
next determined the extent to which these molecules undergo
stimulated secretion in the presence or absence of the population
of short-lived punctate organelles. Histamine stimulation of Na-
butyrate or IL-1–treated cells led to a significant increase in the
secretion of tPA or IL-8, IL-6, and MCP-1, but not GRO- (Figure
7Ai-iv). Stimulated secretion of endogenous tPA, IL-8, IL-6, and
MCP-1 was maintained after BFA (5M, 1-hour) or CHX (5M,
24-hour) treatment, conditions where the short-lived punctate
organelles were absent (supplemental Figure 5) and unstimulated
secretion substantially reduced (Figure 5). Consistent with this,
immunofluorescence analysis of BFA- or CHX-treated cells re-
vealed WPBs containing tPA or IL-8, IL-6, MCP-1, or GRO-
(supplemental Figure 5). In CHX-treated cells, ionomycin (1M)
led to even larger increases in secretion of tPA, IL-8, IL-6, and
MCP-1, and reproducibly evoked a small but significant increase in
GRO- secretion (eg, Figure 7Av). Analysis of the storage
efficiency of tPA and cytokines revealed that all were very poorly
stored within the cells compared with VWF (Figure 7B), irrespec-
tive of expression levels (eg, IL-8 storage efficiency was 1%–2%
over a 10-fold range of expression produced by IL-1, 0.1-10 ng/
mL; not shown).
EGFP expressed in the lumen of the secretory pathway
appears in WPBs but is poorly stored
The low storage efficiency of cytokines in HUVECs suggested that
their presence in WPBs might reflect an inability of the secretory
pathway to completely exclude (or subsequently remove) these
molecules from nascent WPBs rather than them having “sorting”
information specifically directing them into WPBs. If cytokines are
found in WPBs simply because they cannot be efficiently excluded,
then any nonphysiologic protein should also be stored in WPBs to a
similar low degree. Consistent with this, expression of lumEGFP
resulted in its incorporation into WPBs (Figure 7C) and was
secreted in response to histamine or ionomycin (supplemental
Figure 7B). Pulse-chase or ELISA analysis showed that only
approximately 4% to 5% of the biosynthetic material was stored
(Figure 7B; supplemental Figure 7A).
Discussion
We provide evidence that the tPA organelle and type-2 organelle
represent a single compartment responsible for the majority of
unstimulated secretion of tPA or cytokines. We suggest that the
presence of cytokines and tPA within WPBs arises not from specific
sorting to WPBs but rather from an exclusion or removal mecha-
nism that is close to but not 100% efficient. The long-lived nature
of WPBs and their accumulation within the cells during periods of
high expression of cytokines result in a pool of nonexcluded
(missorted) molecules within WPBs that constitute the majority of
material available for stimulated secretion.
Unstimulated secretion of tPA-EGFP and cytokines arises from
a common compartment
Based on their similar morphology, subcellular distribution, com-
mon lack of WPB-specific marker proteins, and depletion after
BFA (or CHX) treatment, we conclude that the tPA-EGFP puncta
observed here represent the same punctate compartment in which
endogenous tPAis found in nontransfected cells. The type-2 chemokine-
containing organelle shares a similar morphology, subcellular
distribution, and lack of WPB markers; however, its distinct
identity was suggested by the failure of overexpressed tPA to
colocalize with these organelles.5 In that study, there was a
conspicuous absence of tPA immunoreactivity in the Golgi region
of cells transfected with the tPA-expression vector. Crucially, in our
opinion, no epitope tag appears to have been included on the
overexpressed tPA that could have independently verified whether
the tPA immunoreactivity seen in the transfected cells was the
result of transgene expression or endogenous protein. This leads us
to propose that, at least in the example shown in Oynebraten et al,5
the exogenous tPA may not have expressed (to detectable levels),
Figure 6. pH in the tPA-EGFP-containing granule. (Top panel) Distribution of pH in
tPA-EGFP containing puncta, determined from measurements of individual tPA-
EGFP puncta using the NH4Cl pulse technique11 6 hours after Nucleofection (mean
pH; pH 6.10 	 0.32, n  89 organelles, 11 cells). (Bottom panel) Similar data
obtained 24 hours after Nucleofection (mean pH; pH 6.11 	 0.25, n  52 organelles,
4 cells). The distribution of pH within individual mature WPBs containing tPA-EGFP is
shown as a histogram with dashed lines (mean pH; pH 5.27 	 0.23, n  56
organelles, 10 cells). Intragranule pH was determined as described in “pH in the tPA
organelle.”
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and the peripheral tPA immunoreactivity observed reflected endog-
enous material synthesized before up-regulation of GRO- expres-
sion by IL-1. On the basis of these data, we do not think that an
unequivocal discrimination between the type-2 organelle and the
tPA organelle is possible.
Here we show, in cells clearly expressing tPA-EGFP, the
colocalization of tPA-EGFP with endogenous GRO- and MCP-1
puncta. tPA-EGFP also colocalized with endogenous IL-8, IL-6, or
eotaxin-3 puncta. Exogenously expressed hIL-8 colocalized with
endogenous tPA puncta, as did endogenous eotaxin-3. Colocaliza-
tion of endogenous GRO--containing, VWF-negative puncta with
endogenous IL-8 or IL-6 puncta suggests that this small punctate
organelle represents a common compartment for many small
molecules whose expression is up-regulated by inflammatory
cytokines. The appearance of cytokine-containing puncta in IL-1–
treated cells is accompanied by a large increase in unstimulated
secretion of these molecules (Figure 7; supplemental Figure 1).
Unstimulated exocytosis of punctate tPA-EGFP organelles in ECs
(14 and supplemental Figure 6) suggests that these organelles could
represent a pathway primarily responsible for unstimulated secre-
tion. Data presented in Figure 4 show that this is the case. The
exponential time course for loss of these granules after BFA
treatment indicates that the final plasma membrane fusion step in
unstimulated exocytosis is not rate limiting; this organelle is not a
true storage organelle like the WPB. Consistent with its short
life-time, the intra-tPA organelle pH was similar to that of the TGN
(
 pH 6.2)33 and showed no evidence of further acidification as
seen for WPBs.11
The majority of stimulated cytokine secretion arises from WPBs
We found MCP-1 in WPBs, and also GRO-, although its levels
were very low and often difficult to detect because of the numerous
small punctate organelles (supplemental Figures 3B, 5). Their
presence in WPBs was most clearly revealed after depletion of
punctate organelles by BFA or CHX treatment (supplemental
Figure 5). IL-6 was also present in WPBs in a pattern similar to that
reported for IL-8 and eotaxin-3.24,25 Consistent with this, hista-
mine- or ionomycin-evoked secretion of IL-8, IL-6, MCP-1, and
tPA persisted largely unaltered after BFA or CHX treatment.
n-Butanol, a partial but selective inhibitor of WPB exocytosis,12
partially inhibited stimulated secretion of tPA, IL-8, and the
VWF-propolypeptide in BFA-treated cells (supplemental Figure
8), consistent with this secreted material arising from WPBs. A
weak stimulated secretion of GRO- was only seen in response to
ionomycin in CHX-treated cells, consistent with very low levels of
GRO- immunoreactivity seen in some WPBs. These data imply
that exocytosis of the small punctate organelles is either insensitive
Figure 7. BFA- and CHX-insensitive stimulated secretion and storage efficiency of tPA and cytokines in HUVECs. (A) Top panels: Histamine-stimulated secretion of tPA
(i), IL-8 (ii), IL-6 (iii), MCP-1 (iv), and GRO- (v) in the absence (BFA vehicle, 1 hour) or after BFA treatment (1 hour) as indicated. Cells were pretreated for 24 hours with either
3mM Na-butyrate (i) or 1 ng/mL rhIL-1 (ii-v) before experiments. Bottom panels: Histamine- or ionomycin-stimulated secretion of tPA and the cytokines in control (CHX vehicle
for 24 hours) or CHX-treated (24 hours) cells as indicated. Na-butyrate or rhIL-1 was included in the media during CHX treatment. Data shown in each case are an individual
experiment, carried out in triplicate, and are representative of 3 or 4 replicate experiments. *P  .05. **P  .001. (B) Storage efficiency for VWF, tPA, and lumEGFP determined
by pulse-chase methodologies and for lumEGFP, IL-8, IL-6, MCP-1, and GRO- determined by specific ELISA methodologies as indicated. Pulse-chase data in each case are
the mean of 2 experiments each carried out in triplicate. Error bars represent the range of the duplicate values. ELISA data are the mean of 3 or 4 separate experiments carried
out either in triplicate (LumEGFP) or in duplicate (the cytokines). (C) lumEGFP fluorescence (left panel) and VWF immunoreactivity (right panel) in a cell 48 hours after
Nucleofection with lumEGFP. Arrowheads indicate lumEGFP-positive WPBs.
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or only very weakly sensitive to secretagogue stimulation. To
examine this, we imaged live cells expressing tPA-EGFP (and
proregion-mRFP or mRFP-Rab27a to mark tPA-EGFP containing
WPBs) or proregion-EGFP alone (a specific WPB marker). In
approximately 50% of the cells studied, stimulation with histamine
or ionomycin failed to evoked fusion of tPA-EGFP puncta. In the
remaining cells, a variable but weak response was seen comprising
fusion of approximately 1% to 5% of the fluorescent puncta
(supplemental Figure 6). The prefusion pH values within these
organelles (supplemental Figure 6C), determined by epifluores-
cence measurements,11 were similar to those determined using
NH4Cl (Figure 6). In contrast, WPB exocytosis was seen in all
cells studied with approximately 70% degranulation during strong
stimulation (supplemental Figure 6). Together, the ELISA and live
cell imaging data confirm that the majority of stimulated secretion
of cytokines and tPA arises from WPB exocytosis. The small
punctate organelle is at best poorly responsive to histamine or
ionomycin.
Are cytokines sorted to or excluded from the WPBs? Identifica-
tion of IL-8 and eotaxin-3 in WPBs has led to the suggestion that
these soluble molecules are “sorted” into this organelle,5,23,24,34
perhaps through interactions with VWF.23 Other soluble molecules
that bind VWF and are detectable in WPBs include osteoprotegerin
and factor VIII,35-37 raising the attractive idea that VWF may act as
a molecular chaperone for sorting to WPBs. However, an elegant
series of studies have shown that binding of factor VIII to VWF
plays no role in its inclusion in WPBs.38,39 Thus, VWF binding does
not necessarily play a role in the entry of molecules to WPBs.
Evidence presented here and from other studies suggests that the
cytokines or tPA may not be actively sorted to WPBs but instead are
not completely excluded from these organelles. First, the majority
of cytokine material produced after up-regulation by IL-1 is not
stored within the cells (Figure 7). Consistent with this, pulse-chase
experiments show that virtually all de novo produced IL-8 is
secreted from ECs within approximately 60 minutes of its synthe-
sis.23 Similar results have been reported for tPA40 and were
confirmed here (Figure 7). Because cytokine immunoreactivity
could also be seen in non-WPB compartments (eg, Golgi associ-
ated) after CHX treatment (supplemental Figure 5), the amount
of material specifically in WPBs probably represents only a
fraction of the approximate 1% of cell-associated (stored) material
(Figure 7B). In comparison, the storage efficiency of VWF was
approximately 50% (Figure 7B). Thus, if cytokines or tPA are
sorted to WPBs, this process is very inefficient, and is no more
efficient than that of a nonmammalian nonsecretory protein
(lumEGFP) targeted to the secretory pathway (Figure 7B-C).
Two models for sorting of soluble luminal proteins to regulated
secretory granules have been postulated.41,42 The “sorting for
entry” model postulates specific mechanisms directing soluble
proteins into immature secretory granules during their formation,
whereas the “sorting by retention” model postulates that entry of
proteins into immature secretory granules is not particularly
selective. In the latter model, the final composition of the organelle
depends on processes, such as cargo aggregation and the removal
of soluble proteins from the organelle during its maturation. It is
now clear that many, if not all, proteins destined largely for
constitutive secretion can enter newly forming regulated secretory
granules without the need for specific sorting signals.41,43 In
pancreatic -cells, no endogenous secretory protein specific only
to the constitutive pathway has yet been identified.43 The data
presented here are consistent with such a model and are supported
by our observation that lumEGFP can enter WPBs, and similar data
showing that nonsecretory proteins, when directed into the ER,
can enter the regulated secretory pathway.41 The very low level of
retention of molecules, such as IL-8, may arise through weak
binding to VWF,23 nonspecific entrapment within the condensing
proregion-VWF paracrystal,44 or incomplete removal during or-
ganelle maturation. Fluorescence recovery after photobleaching
analysis of eotaxin-3-EGFP and lumEGFP has show that these
molecules diffuse freely in the immature WPBs, suggesting they
enter via and remain in the fluid phase.45
According to the simple model outlined in the preceding
paragraph, molecules such as IL-8, IL-6, GRO-, MCP-1, and
eotaxin-3 and tPA are destined primarily for unstimulated secretion
but enter the WPBs because of an exclusion or removal mechanism
that is not quite (but almost) 100% efficient. If this is the case, then
the presence of such molecules in WPBs reflects missorting and has
implications for how we view the physiologic or pathophysiologic
roles of such molecules when secreted from WPBs.
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